Valbiotis reports 130% revenue growth in first half of 2026

Valbiotis, a French laboratory specializing in cardiometabolic health, reported its first-half 2026 results, showing a 130% increase in half-year revenue to €0.8 million. The company noted a limited increase in operating expenses, which rose 8% to €5.5 million.

Key operational developments include a fully operational sales organization in France and the launch of the Valbiotis PRO® Foie range. Internationally, the company has signed three key agreements, with a Chinese joint venture expected to begin sales by the end of 2026 and product registrations in the Middle East anticipated in the first half of 2027.

As of June 30, 2026, Valbiotis held a cash position of €11.7 million, supported by a recent capital increase, providing a cash runway through the end of 2027. Despite the growth, the company has withdrawn its previously communicated financial ambitions for the 2026-2030 period, while expressing confidence in accelerating its growth trajectory starting in the second half of 2026.